GME GROUP (08188) Honored with the Hong Kong Securities Analysts Association Market Share Annual Award 2026
GME GROUP (08188) Announcement: The Company announces that on October 16, 2026, at the "Listed Company Annual Awards 2026" presentation ceremony organized by the Hong Kong Securities Analysts Association and HOY TV, it was presented with the award "Hong Kong Securities Analysts Association Market Share Annual Award 2026." The award recognizes listed companies with outstanding performance, honoring their excellent corporate governance, sustained growth, and innovative capabilities, thereby highlighting the high-quality development and robust vitality of Hong Kong's financial market.
GME GROUP (08188) announced that on October 16, 2026, the Company was presented with the "Hong Kong Securities Analysts Association Market Share Annual Award 2026" at the "Listed Company Annual Awards 2026" presentation ceremony organized by the Hong Kong Securities Analysts Association and HOY TV. The award recognizes listed companies with outstanding performance, honoring their excellent corporate governance, sustained growth and innovative capabilities, and highlighting the high-quality development and robust vitality of Hong Kong's financial market.
Related Articles
Agricultural Bank Of China (01288) will distribute an interim dividend of HK$1.522165 per 10 shares on November 25.
ASCENTAGE(06855) Lisaftoclax Receives Breakthrough Therapy Designation for the Treatment of Treatment-Naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
HAITONG INT'L Zhang Yidong: AI is expected to drive innovative drugs from performance improvement toward a revaluation of R&D asset value
Agricultural Bank Of China (01288) will distribute an interim dividend of HK$1.522165 per 10 shares on November 25.
ASCENTAGE(06855) Lisaftoclax Receives Breakthrough Therapy Designation for the Treatment of Treatment-Naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
HAITONG INT'L Zhang Yidong: AI is expected to drive innovative drugs from performance improvement toward a revaluation of R&D asset value
